Are Analysts Bullish C. R. Bard, Inc. (NYSE:BCR) After Last Week?

December 7, 2017 - By Michael Collier

 Are Analysts Bullish C. R. Bard, Inc. (NYSE:BCR) After Last Week?
Investors sentiment decreased to 0.58 in 2017 Q2. Its down 0.30, from 0.88 in 2017Q1. It fall, as 99 investors sold C. R. Bard, Inc. shares while 273 reduced holdings. 103 funds opened positions while 111 raised stakes. 55.14 million shares or 10.97% less from 61.93 million shares in 2017Q1 were reported.
South State Corp invested in 0.49% or 12,110 shares. Teacher Retirement Systems Of Texas stated it has 753 shares. Comm Bankshares has 10,262 shares for 0.05% of their portfolio. 19,193 are owned by Valley Advisers. Janney Montgomery Scott Lc invested in 0.01% or 3,542 shares. Northwestern Mutual Wealth Management invested in 0% or 266 shares. Gvo Asset Ltd stated it has 3.37% of its portfolio in C. R. Bard, Inc. (NYSE:BCR). Dearborn Ltd Limited Liability Company holds 1.12% or 47,877 shares in its portfolio. Advisor Ptnrs Limited Liability accumulated 1,360 shares. Daiwa Group reported 3,980 shares. Aqr Cap Mngmt Limited has invested 0.03% of its portfolio in C. R. Bard, Inc. (NYSE:BCR). 4,414 are held by Commonwealth Bank & Trust Of Australia. Fred Alger Mgmt Inc accumulated 50 shares. Alabama-based Buckingham Management has invested 0.11% in C. R. Bard, Inc. (NYSE:BCR). Ftb Advsr reported 0.06% stake.

C. R. Bard, Inc. (NYSE:BCR) Ratings Coverage

Among 15 analysts covering CR Bard (NYSE:BCR), 4 have Buy rating, 0 Sell and 11 Hold. Therefore 27% are positive. CR Bard had 32 analyst reports since August 27, 2015 according to SRatingsIntel. The company was maintained on Tuesday, September 12 by Jefferies. The rating was initiated by KeyBanc Capital Markets with “Sector Weight” on Thursday, August 27. The stock of C. R. Bard, Inc. (NYSE:BCR) has “Market Perform” rating given on Wednesday, April 26 by BMO Capital Markets. The firm earned “Hold” rating on Monday, July 10 by BMO Capital Markets. On Thursday, November 12 the stock rating was initiated by Citigroup with “Buy”. Zacks downgraded the stock to “Hold” rating in Monday, September 7 report. As per Thursday, June 29, the company rating was maintained by Jefferies. The company was maintained on Wednesday, July 27 by Barclays Capital. The stock of C. R. Bard, Inc. (NYSE:BCR) earned “Hold” rating by Jefferies on Wednesday, July 27. The firm earned “Equal-Weight” rating on Monday, November 6 by Barclays Capital. Below is a list of C. R. Bard, Inc. (NYSE:BCR) latest ratings and price target changes.

06/11/2017 Broker: Barclays Capital Rating: Equal-Weight Old Target: $245 New Target: $337 Maintain
11/10/2017 Broker: BMO Capital Markets Rating: Hold New Target: $317.0 Maintain
22/09/2017 Broker: Needham Rating: Hold Maintain
12/09/2017 Broker: Jefferies Rating: Hold New Target: $317.0 Maintain
31/08/2017 Broker: BMO Capital Markets Rating: Hold New Target: $317.0 Maintain
28/07/2017 Broker: Cowen & Co Rating: Hold New Target: $317.0000 Maintain
28/07/2017 Broker: Needham Rating: Hold
10/07/2017 Broker: BMO Capital Markets Rating: Hold New Target: $317.0000 Maintain
29/06/2017 Broker: Jefferies Rating: Hold New Target: $317.0000 Maintain

The stock increased 0.06% or $0.19 during the last trading session, reaching $332.07. About 569,167 shares traded or 16.85% up from the average. C. R. Bard, Inc. (NYSE:BCR) has risen 40.70% since December 7, 2016 and is uptrending. It has outperformed by 24.00% the S&P500.

C. R. Bard, Inc., together with its subsidiaries, designs, makes, packages, distributes, and sells medical, surgical, diagnostic, and patient care devices worldwide. The company has market cap of $24.21 billion. The firm offers vascular products, such as percutaneous transluminal angioplasty catheters, chronic total occlusion catheters, guidewires, fabrics, meshes, introducers, and accessories; valvuloplasty balloons; peripheral vascular stents, self-expanding and balloon-expandable covered stents, and vascular grafts; vena cava filters; biopsy devices; and a range of minimally invasive devices for the treatment of peripheral vascular and end-stage renal diseases. It has a 43.8 P/E ratio. It also provides urology products, including Foley catheters to reduce the rate of urinary tract infections; fecal incontinence products; brachytherapy devices and radioactive seeds for the treatment of prostate cancer; intermittent urinary drainage catheters, and urine monitoring and collection systems; ureteral stents; specialty devices for stone removal procedures; surgical slings and pelvic floor repair products; catheter stabilization devices; and products for therapeutic hypothermia.

More news for C. R. Bard, Inc. (NYSE:BCR) were recently published by: Bizjournals.com, which released: “What Jabil’s new director signals about the company’s future” on November 30, 2017. Investorplace.com‘s article titled: “CR Bard (BCR) a Strong Buy on Exceptional Quant Score” and published on November 28, 2017 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.